Table 1.
Group A (n = 18) | Group B (n = 45) | p | |
---|---|---|---|
Biochemical picture | |||
Euthyroidism | 72.3% | 95.6% | 0.03 |
Overt hypothyroidism | 16.6% | 0% | 0.005 |
Subclinical hypothyroidism | 0% | 2.2% | 0.52 |
Overt hyperthyroidism | 11.1% | 2.2% | 0.10 |
Clinical picture | |||
Association with AITDsa | 33.3% | 8.9% | 0.02 |
Cytological stagesb | |||
III | 22.2% | 22.2% | 1.00. |
IV | 27.8% | 33.3% | 0.67 |
V | 27.8% | 28.9% | 0.93 |
VI | 22.2% | 15.6% | 0.53 |
Tumor histology | |||
Papillary carcinoma | 55.6% | 66.7% | 0.40 |
Papillary follicular variant | 33.3% | 31.1% | 0.86 |
Follicular carcinoma | 11.1% | 2.2% | 0.13 |
Risk levelsc | |||
Low | 55.5% | 75.6% | 0.26 |
Intermediate | 27.8% | 22.2% | 0.73 |
High | 16.7% | 2.2% | 0.03 |
aAutoimmune thyroid diseases
bAccording to the Bethesda system (Reference No. 14)
cAccording to the staging system described by Francis et al. (Reference No.10)